Ocugen (OCGN) Set to Announce Quarterly Earnings on Friday

Ocugen (NASDAQ:OCGN) will be announcing its earnings results before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Ocugen (NASDAQ:OCGN) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.02. The business had revenue of $1.14 million during the quarter. During the same quarter in the previous year, the business posted ($0.10) EPS. On average, analysts expect Ocugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ocugen Trading Down 0.8 %

Shares of OCGN opened at $0.95 on Wednesday. The business’s 50-day moving average price is $1.05 and its 200 day moving average price is $1.36. The stock has a market capitalization of $273.50 million, a P/E ratio of -5.00 and a beta of 3.75. Ocugen has a 1-year low of $0.35 and a 1-year high of $2.11. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.09.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Maxim Group assumed coverage on Ocugen in a research note on Tuesday, October 15th. They issued a “buy” rating and a $4.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Ocugen in a research note on Wednesday, October 23rd.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.